Nature Communications (May 2021)
Clonal evolution and clinical implications of genetic abnormalities in blastic transformation of chronic myeloid leukaemia
- Yotaro Ochi,
- Kenichi Yoshida,
- Ying-Jung Huang,
- Ming-Chung Kuo,
- Yasuhito Nannya,
- Ko Sasaki,
- Kinuko Mitani,
- Noriko Hosoya,
- Nobuhiro Hiramoto,
- Takayuki Ishikawa,
- Susan Branford,
- Naranie Shanmuganathan,
- Kazuma Ohyashiki,
- Naoto Takahashi,
- Tomoiku Takaku,
- Shun Tsuchiya,
- Nobuhiro Kanemura,
- Nobuhiko Nakamura,
- Yasunori Ueda,
- Satoshi Yoshihara,
- Rabindranath Bera,
- Yusuke Shiozawa,
- Lanying Zhao,
- June Takeda,
- Yosaku Watatani,
- Rurika Okuda,
- Hideki Makishima,
- Yuichi Shiraishi,
- Kenichi Chiba,
- Hiroko Tanaka,
- Masashi Sanada,
- Akifumi Takaori-Kondo,
- Satoru Miyano,
- Seishi Ogawa,
- Lee-Yung Shih
Affiliations
- Yotaro Ochi
- Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University
- Kenichi Yoshida
- Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University
- Ying-Jung Huang
- Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital-Linkou
- Ming-Chung Kuo
- Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital-Linkou
- Yasuhito Nannya
- Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University
- Ko Sasaki
- Department of Hematology and Oncology, Dokkyo Medical University
- Kinuko Mitani
- Department of Hematology and Oncology, Dokkyo Medical University
- Noriko Hosoya
- Laboratory of Molecular Radiology, Center for Disease Biology and Integrative Medicine, Graduate School of Medicine, The University of Tokyo
- Nobuhiro Hiramoto
- Department of Hematology, Kobe City Medical Center General Hospital
- Takayuki Ishikawa
- Department of Hematology, Kobe City Medical Center General Hospital
- Susan Branford
- Department of Genetics and Molecular Pathology, Centre for Cancer Biology, SA Pathology
- Naranie Shanmuganathan
- Department of Genetics and Molecular Pathology, Centre for Cancer Biology, SA Pathology
- Kazuma Ohyashiki
- Department of Hematology, Tokyo Medical University
- Naoto Takahashi
- Department of Hematology, Nephrology, and Rheumatology, Akita University Graduate School of Medicine
- Tomoiku Takaku
- Department of Hematology, Juntendo University School of Medicine
- Shun Tsuchiya
- Department of Hematology, Juntendo University School of Medicine
- Nobuhiro Kanemura
- Department of Hematology, Gifu University Hospital
- Nobuhiko Nakamura
- Department of Hematology, Gifu University Hospital
- Yasunori Ueda
- Department of Hematology and Oncology, Kurashiki Central Hospital
- Satoshi Yoshihara
- Department of Hematology, Hyogo College of Medicine Hospital
- Rabindranath Bera
- Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital-Linkou
- Yusuke Shiozawa
- Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University
- Lanying Zhao
- Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University
- June Takeda
- Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University
- Yosaku Watatani
- Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University
- Rurika Okuda
- Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University
- Hideki Makishima
- Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University
- Yuichi Shiraishi
- Laboratory of DNA Information Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo
- Kenichi Chiba
- Laboratory of DNA Information Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo
- Hiroko Tanaka
- Laboratory of DNA Information Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo
- Masashi Sanada
- Department of Advanced Diagnosis, Clinical Research Center, National Hospital Organization Nagoya Medical Center
- Akifumi Takaori-Kondo
- Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University
- Satoru Miyano
- Laboratory of DNA Information Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo
- Seishi Ogawa
- Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University
- Lee-Yung Shih
- Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital-Linkou
- DOI
- https://doi.org/10.1038/s41467-021-23097-w
- Journal volume & issue
-
Vol. 12,
no. 1
pp. 1 – 13
Abstract
In chronic myeloid leukaemia (CML), the drivers of blast crisis and resistance to tyrosine kinase inhibitors are not fully characterised. Here, the authors analyse a cohort of CML samples with genomic technologies and find that at least one driver alteration is associated with progression and worse prognosis.
